KMT2D and neoplasm: By assessing the 16 patients with low infiltration (<10%), 7/16 harboured pathogenic mutations in TP53, ATM, KMT2D or ARID1A with lower VAFs ranging from 1.8- < 4%, which appeared to be clonal when correcting for tumour cell infiltration.